Production (Stage)
Seres Therapeutics, Inc.
MCRB
$7.09
$0.040.57%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 64.00K | 374.00K | 126.85M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 64.00K | 374.00K | 126.85M |
| Cost of Revenue | 29.49M | 25.96M | 23.85M | 25.63M | 54.55M |
| Gross Profit | -29.49M | -25.96M | -23.85M | -25.63M | 71.92M |
| SG&A Expenses | 53.12M | 56.18M | 57.69M | 64.42M | 76.41M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -2.59M | -2.59M | -2.59M | -2.59M | 2.11M |
| Total Operating Expenses | 116.59M | 123.79M | 131.98M | 147.39M | 193.00M |
| Operating Income | -116.59M | -123.79M | -131.98M | -147.39M | -66.52M |
| Income Before Tax | -66.86M | -132.45M | -151.53M | -141.51M | -62.08M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -66.86 | -132.45 | -151.53 | -141.51 | -62.08 |
| Earnings from Discontinued Operations | 139.81M | 132.58M | 126.05M | -20.60M | -20.60M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 72.95M | 136.00K | -25.48M | -162.11M | -82.68M |
| EBIT | -116.59M | -123.79M | -131.98M | -147.39M | -66.52M |
| EBITDA | -111.60M | -118.32M | -125.96M | -141.10M | -60.12M |
| EPS Basic | 9.22 | -0.03 | -4.54 | -23.63 | -12.00 |
| Normalized Basic EPS | -8.14 | -9.55 | -13.04 | -12.86 | -5.59 |
| EPS Diluted | 9.09 | -0.15 | -4.62 | -23.72 | -12.12 |
| Normalized Diluted EPS | -8.14 | -9.55 | -13.04 | -12.86 | -5.67 |
| Average Basic Shares Outstanding | 32.48M | 31.08M | 29.02M | 27.80M | 26.61M |
| Average Diluted Shares Outstanding | 32.49M | 31.08M | 29.02M | 27.80M | 26.72M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |